• Each of the 17 startups gets a €560,000 convertible loan — not priced equity — plus lab space in BII's Copenhagen facility and fundraising-prep support.
• The cohort is funded off the Novo Nordisk Foundation's DKK 5.5 billion (€736 million) commitment for 2026-2035, announced January 15, 2026.
• That mandate is meant to lift BII's annual startup intake from roughly 20 companies to 30, and backs checks of up to €1.8 million per startup.
• BII now says it has backed more than 140 companies total, up from the "more than 130" it cited in the foundation's January announcement — roughly ten added in eight months.
• Undisclosed: individual company valuations, the loans' conversion terms, and how much of the €736 million commitment has actually been drawn down so far.

BioInnovation Institute (BII) is putting €9.52 million into 17 early-stage, research-based startups — €560,000 per company, structured as a convertible loan rather than priced equity — the Copenhagen institute confirmed via a Tech.eu report published September 16, 2026. The cohort is the first sized against a mandate that got much bigger this year: on January 15, 2026, the Novo Nordisk Foundation committed DKK 5.5 billion (€736 million) to BII, covering 2026 through 2035, explicitly to let the institute raise its annual startup intake from roughly 20 companies to 30.

The instrument: convertible debt, not a priced round

BII structures its support as a convertible loan — capital that converts into shares on a future qualifying round rather than pricing the company today, which lets the institute write checks without forcing an early valuation. Recipients also get lab space inside BII's Copenhagen facility, access to its network of entrepreneurs, investors and domain experts, and help preparing for their next fundraise. Trine Bartholdy, BII's Chief Business Officer, said the institute is capturing research from Danish and European universities and hospitals — a wider geographic net than a Denmark-only mandate implies.

Where the mandate comes from

The step-up traces to a single grant. Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said the DKK 5.5 billion commitment gives BII the opportunity "to expand its reach and further strengthen its position as a European powerhouse for innovation." The foundation's support capacity per startup can run up to €1.8 million, and the ten-year frame is meant to lift BII's annual startup count from about 20 to roughly 30 — a scale-up in cadence, not just in check size.

The cohort, and BII's running tally

The 17 companies — among them Fibernex, Sylvia Health, Corcellys Therapeutics, Launch Bioindustries and Copenhagen Microsystems — span healthcare, biotech and deep-tech research, per Tech.eu. BII now says it has backed more than 140 companies since 2018, up from the "more than 130" the foundation cited in its January announcement — roughly ten additions in eight months. Those portfolio companies have together attracted more than DKK 7 billion in external funding to date, the foundation said, and BII's CEO Jens Nielsen credited the foundation's backing directly: "None of this would be possible without the long-term support from the Novo Nordisk Foundation."

The verdict

Smaller, more numerous convertible loans is the right instrument for an institute trying to prove it can raise the number of companies it backs each year, not just enlarge individual bets — €560,000 buys roughly a year of runway for a pre-seed lab spinout, not a Series A substitute, and BII isn't pretending otherwise. The number worth tracking isn't this cohort's €9.52 million; it's whether BII actually reaches 30 companies a year under the new mandate, and how much of the €736 million commitment gets drawn down between now and 2035.